Spicing Things Up Beyond sauces, The McCormick Company is also making a bold bet on flavor of its own, as reported by The Wall Street Journal
By learning to recognize the signs, interpret the labs, and individualize the path to healing, clinicians can help patients reclaim their cognitive clarity, energy, and quality of life, often after years of unexplained illness
In 2024, incretin-based therapies, including GLP-1 and GIP agonists, accounted for 13 major deals worth $25.6 billion
Before starting GLP-1 medications: Ensure you've had a recent diabetic eye screening (within the past 12 months) Discuss your retinopathy status with your prescribing clinician If you have known retinopathy, consider ophthalmology review before initiation Understand that gradual dose titration may help avoid very rapid changes in blood glucose, which is a general principle in diabetes management During treatment: Attend all scheduled diabetic eye screening appointments without fail If you have pre-existing retinopathy, your diabetes team may consider more frequent monitoring based on your individual clinical situation Control blood pressure to target levels (below 140/90 mmHg, or below 130/80 mmHg if you have kidney, eye or cerebrovascular damage, if tolerated) [13] Maintain good overall glycaemic control whilst avoiding excessively rapid HbA1c reductions when possible Stop smoking if applicable, as tobacco significantly worsens diabetic eye disease Manage cholesterol levels according to NICE guidance for cardiovascular risk reduction Communicate openly with your healthcare team about any visual symptoms, even if they seem minor
Novo Nordisk recently announced that the drugs list price will be lowered from over $1,000 to $675, which may make insurers more likely to cover it
This could affect energy balance, cholesterol levels, or insulin sensitivity
